MediGene AG | Mutual Funds
Mutual Funds that own MediGene AG
iShares TecDAX (DE)
343,944
1.4%
0
0.47%
09/07/2018
PWM Vermoegensfondsmandat - DWS - High Conviction Equity (EUR)
293,000
1.19%
-13,000
4.69%
07/31/2018
Credit Suisse Equity Fund (Lux) - Small & Mid Cap Germany
293,000
1.19%
0
0.84%
06/29/2018
DFA Continental Small Company Series
108,058
0.44%
51,975
0.03%
01/31/2018
88,000
0.36%
88,000
1.54%
02/28/2018
Aviva Investors Investment Funds ICVC - European Equity Fund
82,751
0.34%
-35,629
0.54%
10/15/2017
Warburg - Daxtrend - Fonds
38,896
0.16%
1,812
1.57%
06/29/2018
LBBW Aktien Deutschland
37,000
0.15%
4,000
0.54%
06/29/2018
AM Fortune Fund Offensive
27,000
0.11%
0
1.29%
06/29/2018
24,715
0.1%
1,619
0.45%
08/31/2018
| Address |
Lochhamer Straße 11
Martinsried Bayern (Bavaria) 82152
Germany
|
|
Employees
|
- |
| Website |
http://www.medigene.de |
| Updated |
07/08/2019 |
| MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. |
